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Mechanisms of human natural resistance to HIV: A summary 
of ten years of research in the Colombian population
María T. Rugeles, Paula A. Velilla, Carlos J. Montoya
Grupo Inmunovirología, Facultad de Medicina, Universidad de Antioquia, Medellín, Colombia
The natural history of human immunodeficiency virus type-1 (HIV-1) infection is a complex and variable 
process that, similarly to other infections, has clearly demonstrated the existence of mechanisms 
of human natural resistance. The resistance either inhibits the establishment of infection or delays 
disease progression. When there is continuous exposure to infectious viral particles, several genetic 
and immunological mechanisms are essential to lead to resistance to HIV-1 infection/progression. 
The objective of this manuscript was to review the different mechanisms so far proposed to be 
responsible for HIV-1 resistance and to present the main results derived from 10 years of research in 
this area among Colombian subjects. In particular, this review focuses on determining the mechanisms 
involved in the protection of a group of individuals repeatedly exposed to the virus but who remained 
exempt of serological and clinical evidence of HIV-1 infection. Although the studies carried out in our 
research group corroborated the protective role of some of the previously proposed mechanisms of 
protection, ongoing research worldwide has made it clear that the phenomenon of human natural 
resistance depends on multiple factors with an important genetic influence, and only multicenter studies 
involving individuals with different genetic backgrounds may determine more universal mechanisms of 
resistance. Increasing our knowledge in this field will contribute to the development of novel preventive 
and therapeutic measures.
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Mecanismos de resistencia natural al VIH en seres humanos: un resumen de 10 años de 
investigación en población colombiana
La historia natural de la infección por el virus de la inmunodeficiencia humana de tipo 1 (VIH-1) 
es un proceso variable y complejo que, en forma similar a otras infecciones, ha hecho evidente la 
existencia de mecanismos de resistencia natural que pueden inhibir el establecimiento de la infección 
o su progresión hacia estadios avanzados. Cuando hay una exposición continua a partículas virales 
infecciosas, varios mecanismos genéticos e inmunitarios son esenciales para que se establezca la 
resistencia. 
El objetivo de este manuscrito fue revisar todos los mecanismos de resistencia al VIH-1, hasta el 
momento propuestos en seres humanos, y presentar los resultados más importantes que se han 
obtenido en diferentes estudios realizados en los últimos 10 años de investigación en esta área, en 
individuos colombianos, particularmente enfocados en determinar los mecanismos involucrados en 
la protección de un grupo de personas que se han expuesto repetidamente al virus, pero que han 
permanecido sin evidencia clínica ni serológica de infección por el VIH-1. 
Aunque los estudios llevados a cabo por nuestro grupo de investigación han corroborado el papel 
protector de algunos de los mecanismos de protección previamente propuestos, la investigación actual 
en esta área, a nivel mundial, ha hecho evidente que el fenómeno de resistencia natural depende 
de múltiples factores con una gran influencia genética, y que sólo mediante estudios multicéntricos 
que involucren individuos con diferente componente genético, podrán establecerse los mecanismos 
universales de protección. Profundizar en el conocimiento en esta área permitirá el desarrollo de 
nuevas medidas preventivas y terapéuticas para la infección por el VIH-1.
Palabras clave: VIH, síndrome de inmunodeficiencia adquirida, control de infecciones, antígenos 
HLA, receptores CCR5, células asesinas naturales, apoptosis, defensinas.
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Human immunodeficiency virus type-1 (HIV-1) 
infection continues to be an expanding epidemic 
worldwide. The risk of HIV-1 transmission varies 
and depends on multiple factors, in particular on 
the type of exposure: blood transfusions represent 
the greatest risk, with 90%, followed by vertical 
transmission with a 10-30% risk in the absence of 
any prophylactic intervention. In contrast, the risk 
of transmission by sharing infectious needles is 
low, 1% similar to the 0.3% risk during accidental 
exposure in health care personnel (1,2). The 
efficiency of sexual transmission is very low; the 
incidence of transmission has been estimated to 
be 0.0001-0.004 per sexual intercourse depending 
in the type of relation: the highest probability of 
infection occurs during male to male intercourses 
(1/10-1/1600), followed by male to women (1/200-
1/2000) and women to male (1/200-1/10000) 
sexual intercourses (3). Oral sex might also lead to 
HIV-1 transmission with a very low frequency (3). 
Although sexual transmission is the least efficient, 
more than 80% of the infections worldwide have 
been acquired through sexual intercourse (4).
During sexual transmission, the virus can pass 
through the mucosa, come into contact mainly with 
macrophages and dendritic cells (DC) and infect 
them (through the CD4, CCR5 or CXCR4 molecules) 
(5-8), or else bind to C-type lectins (Langerin, DC-
SIGN, DEC-205, mannose receptor and dendritic 
cell immunoreceptor-DCIR) expressed on their 
surface, both during infectious and noninfectious 
entry of HIV into these cells (9-11). It was recently 
also demonstrated that CD4+ T cells localized 
in the genital mucosa can be primary targets of 
HIV-1 (12). This occurs when the integrity of the 
epithelium is lost, a frequent phenomenon during 
sexual intercourse. Thereafter, the subsequent 
steps in HIV-1 infection are complex and variable, 
and the infected individuals exhibit different patterns 
of progression (13,14).
Moreover, despite the fact that they are repeatedly 
exposed to HIV-1, certain individuals exhibit no 
serological or clinical evidence of HIV-1 infection; 
they are known as exposed seronegative individuals 
(ESN) (15). This group of persons includes 
individuals who perform repeated unprotected 
sexual intercourses with HIV-1-seropositive 
individuals, neonates born to HIV-1 infected 
mothers, intravenous drug users, receptors of blood 
products from HIV-1-infected donors and health 
care workers with accidental exposures to HIV-1 
(16,17). These individuals have clearly shown the 
existence of mechanisms of natural protection from 
acquired HIV-1 infection.
The mechanisms of human natural resistance 
to infectious diseases are essentially genetic or 
immunological. The main genetic mechanism 
so far reported to be responsible for resistance 
to HIV-1 infection is the ∆32 mutation in the ccr5 
gene (18,19). However, the ∆32/∆32 genotype is 
only present in 2 to 4% of Caucasians individuals 
(7,20,21). Other variants in the chemokine genes 
have been more closely related to slow clinical 
progression than to resistance (22,23). The degree 
of concordance of the major histocompatibility 
complex between mother and neonate has been 
proposed to be a determining factor in the incidence 
of vertical transmission (24), similar to the presence 
of certain class I and class II MHC alleles (25).
Apoptosis or programmed cell death is an important 
mechanism of control during the ontogeny of the 
immune system that also plays a role during the 
immune response to several pathogens (26). Indeed, 
it seems to play a key role in natural resistance to 
Mycobacterium tuberculosis exhibited by some 
strains of mice, preventing the dissemination of M 
tuberculosis (27). During viral infections, apoptosis 
of target cells might also prevent viral dissemination 
(28,29).
The immune response against viruses is initiated by 
innate immune cells such as NK cells, granulocytes 
and γδ T cells that eliminate viruses through cytolytic 
and none-cytolytic mechanisms (30-32). DC and 
macrophages act as antigen presenting cells and 
produce several chemokines and cytokines which 
amplify the immune response (33). The humoral and 
cellular adaptive immune responses complement 
the antiviral action through the production of 
antibodies, cytokines and the cytotoxic activity of 
CD8+ T cells (CTLs) (34). More recently, several 
soluble factors, produced by different cells during 
the immune response have shown great antiviral 
activity as their primary function or as an accidental 
effect.
This article summarizes the different mechanisms 
so far associated with the phenomenon of human 
natural resistance to HIV-1, emphasizing the results 
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of several studies carried out in different cohorts of 
sexually HIV-1 exposed-seronegative individuals 
in Medellin, Colombia during the last 10 years. 
It is important to stress that understanding the 
protective mechanisms involved in HIV-1 infection 
is essential for the development of new preventive 
and therapeutic measures.
Genetic mechanisms for HIV resistance
Polymorphisms and mutations in genes of the 
chemokine system
CCR5 is the port of entry for R5 viral strains, 
which are the primary transmission strains that 
predominate during the asymptomatic phase of 
HIV-1 infection (35). In 1996, a genetic factor, the 
deletion of 32 base pairs in the ccr5 gene known as 
the ∆32 mutation, was associated with a high degree 
of resistance to HIV-1 infection. This mutation 
generates a truncated protein that is not expressed 
on the cell membrane (18,19). Homozygous 
individuals for the ∆32 mutation (∆32/∆32) are highly 
resistant to infection by R5 HIV-1 viral strains while 
heterozygous persons (∆32/ccr5) exhibit delayed 
progression to AIDS (18). Different reports indicate 
that the ∆32/∆32 genotype is only present in 2-4% 
of Caucasian ESN individuals (7,20).
In addition, it is suggested that other polymorphisms 
in the ccr5 gene influence the risk of HIV-1 
transmission and progression (36). The single 
nucleotide polymorphisms (SNP) so far reported in 
the regulatory region of ccr5 (A29G, G208T, G303A; 
T627C, C630T, A676G, C927T) is grouped in 7 
different haplotypes (A-G); these haplotypes might 
dramatically affect disease progression depending 
on the genetic background of the infected individual 
(36).
We evaluated in two studies the presence of 
mutations in the coding region of the ccr5 gene. 
These mutations could be associated with 
natural resistance of HIV-1 exposed-seronegative 
individuals from Medellin, Colombia. In the first 
study (37) we evaluated the frequency of the ∆32 
mutation in the ccr5 gene by the polymerase chain 
reaction (PCR) in a population of 218 individuals: 
29 HIV-1 positive (SP); 39 ESN and 150 individuals 
from the general population (GP). The frequency of 
the ∆32 mutated allele was 1.7% for SP, 3.8% for 
ESN and 2.7% for GP. The heterozygous genotype 
(∆32/ccr5) was found in 3.4% of SP, 2.6% of ESN, 
and in 5.3% of GP. Only one ESN exhibited the 
homozygous genotype ∆32/∆32. These differences 
were not statistically significant.
In the second study, we evaluated the complete 
codifying region of the ccr5 gene (21). Here, we 
screened 50 ESN and 36 SP individuals. A PCR 
was first performed for amplifying exon 4 to obtain 
an 1114 bp product; this product was digested with 
the Hin fI restriction enzyme yielding the followings 
fragments: 355, 215, 202, 159, 144 and 40 bp. 
These restriction fragments were analyzed by single 
strand conformational polymorphisms (SSCP). No 
significant differences in the allelic and genotypic 
frequencies were detected between ESN and SP. 
The frequency of the ∆32 mutated allele was 4.2% 
for SP and 4% for ESN. The heterozygous genotype 
(∆32/ccr5) was observed in 8.3% of SP and 4% of 
Table 1. Observed vs. expected genotypic frequencies. 
Population/genotypes ccr5/ccr5 ccr5/∆32 ∆32/∆32 x2 p
General population observed 142 8 0 0,113 p>0.05
 expected 142,11 7,79 0,11  
HIV-1 positives observed 28 1 0 0,01 p>0.05
 expected 28,01 0,97 0,01
Exposed seronegatives  observed 37 1 1 16,556 p<0.0005
 expected 36,06 2,88 0,06  
  
Table 2. Observed vs. expected genotypic frequencies.
Population/genotypes ccr5/ccr5 ccr5/∆32 ∆32/∆32 x2 p
HIV-1 positives observed 33 3 0 0,0681 p>0.05
 expected 33,0625 2,875 0,0625  
Exposed seronegatives observed 47 2 1 16,556 p<0.005
 expected 46,08 3,84 0,08  
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ESN; only one ESN (2%) has the homozygous 
mutated genotype (∆32/∆32).
However, when we compared the observed vs. the 
expected genotypic frequencies in both studies, 
these frequencies were significantly higher in the 
ESN group (table 1 and 2), suggesting that the 
∆32/∆32 genotype could have a protective effect in 
the population of ESN individuals examined here.
Major histocompatibility complex (MHC)
Several studies in different cohorts of HIV-1-
positive patients show the association between 
alleles expression of particular human leukocyte 
antigen (HLA) and resistance/susceptibility to HIV-1 
infection; this association might be related to the 
influence that specific alleles have on the quality 
of the immune response that is established against 
certain infections. The heterozygosity of HLA class 
I alleles are associated with delayed progression of 
HIV-1 infection (38,39), similar to the association 
found between the presence of the B27 and B57 
HLA alleles with delayed AIDS development (39-42). 
On the other hand, class I HLA allele discordance 
between mother and neonate is associated with 
protection against vertical transmission of HIV-1, 
an effect that is dose-dependent (43). Indeed, 
we postulated that during pregnancy alloantigen 
induce the production of soluble factors, including 
RNases that have anti-HIV-1 activity (44,45). 
Similarly, the presence of the super type HLA 
A2/6802 was associated with a lower risk of vertical 
and horizontal transmission of HIV-1 (45).
In this respect, we investigated whether the 
degree of mother to neonate discordance of class 
I HLA was associated with the ability to produce 
alloantigen-stimulated factor (ASF) with anti-HIV 
activity, and with the expression of RNases in 
placenta (46). The mother and neonate were HLA-
typed and mixed lymphocyte reactions (MLRs) 
were carried out using cord-blood lymphocytes 
and the mother’s peripheral blood mononuclear 
cells. The antiviral activity of the supernatants from 
the MLRs was determined in an in vitro infection 
assay of PHA blasts, measured through the HIV-1 
p24 antigen levels by ELISA. The expression 
of mRNAs for the RNase eosinophil-derived 
neurotoxin (EDN), RNase 1 and angiogenin was 
assessed by RT-PCR. An anti-HIV-1 activity was 
detected in the MLR supernatants (neonate versus 
mother), which was associated with the degree 
of class I HLA allele discordance (figure 1A). This 
class I HLA discordance was also associated with 
the expression of RNase 1 in placenta (figure 1B). 
These findings are consistent with the hypothesis 
that class I HLA allele discordance may induce 
the expression of this RNase in placenta and 
the production of soluble factors with anti-HIV-1 
activity, contributing to the innate resistance to this 
pathogen in the context of vertical transmission.
Immunological mechanisms for HIV resistance
Apoptosis of target cells
Apoptosis is a regulated cell death program that 
can be used by different microorganisms as one of 
their pathogenic mechanisms, but at the same time 
can be used by the host to resist and control the 
establishment of different infections (47). Similarly, 
a variety of pathogens have developed surviving 
strategies blocking or inhibiting apoptosis (48). 
With respect to viral infections, both monocytes 
and macrophages use apoptosis to block early 
events of replication of virus Influenza A (49). In 
addition, BCS-1 cells infected by Theiler’s murine 
encephalomyelitis virus enter in apoptosis limiting 
viral dissemination (50).
During the early phases of HIV-1 infection, 
monocytes/macrophages are the main target cells 
that also act as viral reservoirs (51). Although 
the percentage of HIV-1-infected macrophages 
in tissues (brain, lymphoid node and lung) from 
patients can range from 1-50%, during natural 
infection only 0.001-1% of peripheral blood 
monocytes are infected (52,53). During an in 
vitro model of infection there is a low percentage 
of infected monocytes (54,55), indicating a lower 
susceptibility of monocytes to HIV infection when 
compared to macrophages (56,57).
With this background we carried out a study 
to determine whether apoptosis is one of the 
mechanisms through which some of the ESN 
individuals prevent the establishment of HIV-1 
infection (58). For this study we evaluated 15 SP, 
20 ESN and 20 HIV-1 negative individuals. After 
monocytes and peripheral blood mononuclear cell 
isolation, Annexin V and DiOC6 assays allowed 
assessing spontaneous and HIV-1 induced 
apoptosis. Commercial ELISA determined the levels 
of p24 as indicator of viral replication. The results 
indicated that monocytes from ESN individuals 
suffer significant higher levels of spontaneous 
(figure 2A) and HIV-1 (figure 2B) induced apoptosis 
compared to the control group.
In addition, the levels of p24 were significantly lower 
in supernatants of HIV-1-infected monocytes from 
ESN, than in supernatants from the control group 
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(figure 3). However, the correlation coefficient 
between percentage of cells in apoptosis and 
concentration of p24 antigen was not significant. 
These results suggest that after viral exposure, 
apoptosis of monocytes in some ESN individuals 
could play an important role in avoiding the 
establishment of HIV-1 infection, but other factors 
associated with natural resistance to this infection 
could co-participate in avoiding the process of 
invasion/infection in ESN subjects.
Innate immunity
Innate immunity is the first line of defense and 
is essential for the control of pathogens in skin 
Figure 1. A. ASF production regarding the HLA-I concordance between HIV-1 positive mothers and neonates. Peripheral blood 
mononuclear cells infected with HIV-1 were incubated with supernatants from MLR (ASF neonate vs. mother) for 72 hours, in 
triplicate. The concentration of the p24 antigen in culture supernatants was then evaluated by ELISA, and the percentages of viral 
inhibition were calculated. The horizontal bar corresponds to the median of inhibition regarding the number of HLA-I alleles (locus A 
and B) concordant in mothers and neonates. P value represents the difference between all concordance alleles. 
B. Percentage of placenta samples expressing mRNAs for RNases EDN, RNase 1 and angiogenin. Placenta samples were classified 
according with the number of HLA-I alleles (locus A and B) concordant in mothers and neonates. P value represents the difference 
only based on the expression of RNase 1 between the groups. Data are presented as means and standard deviations 
(SD) or medians and interquartile ranges (IQR). Nonparametric test for trend was used, with a confidence level of 95%. Figure 
reprinted with permission from Banthan Science Publishers Ltd.
Figure 2. Determination of early apoptosis in monocytes, 48 hrs post-HIV-1 infection, evaluated by flow cytometry. Early apoptosis 
was defined as cells positive only for Annexin V. A. Percentage of cells in spontaneous apoptosis. B. Percentage of cells in early 
apoptosis after HIV-1 infection (500 pg/ml of p24 antigen). Horizontal bar in graphics corresponds to median values. Statistically 
significant differences between groups are defined in the upper part of the figure. The result is presented as median and 75th - 25th 
percentile. The statistical comparison among groups was performed using ANVOA not parametric, Kruskal-Wallis with a confidence 
level of 95%. Figure reprinted with permission from Banthan Science Publishers Ltd.
and epithelial and mucous membranes. The 
innate immune response is activated through 
the engagement of toll-like receptors (TLRs) by 
pathogen-associated molecular patterns (PAMPs); 
this response is very heterogeneous and includes 
a cellular, intracellular and a soluble component 
(59). Macrophages, natural killer (NK) cells and NK 
T cells (NKT) very rapidly destroy infected cells, 
while plasmacytoid dendritic cells (pDC) produce 
high amounts of IFN-α, a soluble component with 
very potent antiviral activity. The myeloid dendritic 
cells (mDC), pDC and T cells with invariant TCR 
and restricted by the CD1d molecule, known as 
invariant NKT (iNKT) cells, establish the interaction 
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between the innate and the adaptive branches 
during the anti-infectious immune responses (60).
Recent investigations established the very important 
role played by the innate immunity during the 
evolution of HIV-1 infection (61). Several cells 
from the innate response are target cells for this 
viral infection (62,63), and different alterations of 
this response in HIV-1 infected individuals have 
been described (62,64,65), suggesting that these 
abnormalities could increase the immunodeficiency 
caused by the massive loss of CD4+ T lymphocytes. 
However, the role of the innate response in HIV-1 
resistance has not been established, despite the 
fact that all its components play an active role in 
mucous membranes the main port of viral entry, 
and in the induction of the adaptive immune 
responses. 
Therefore, we investigated the association 
between quantitative and functional parameters of 
pDC, mDC, monocytes, NK and iNKT with human 
natural resistance to HIV-1 infection (66). In total, 
38 SP, 30 ESNs and 35 HIV-1 negative controls 
were examined. The frequency and phenotype of 
the different innate immune cell subpopulations 
were determined by flow cytometry; the functional 
ability of these cells was also evaluated measuring 
the expression of CD86 and CD69, the production 
of the cytokines IL-6, IL-10 and TNF-α by flow 
cytometry and the concentration of IFN-α by ELISA 
in culture supernatants after stimulation of PBMC 
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Figure 3. Concentration of p24 antigen in monocytes cultures. 
In supernatants from monocytes infected with HIV-1, the 
concentration of p24 antigen was determined using a commercial 
ELISA kit. Horizontal bar in graphics corresponds to median 
values. Statistically significant differences between groups are 
defined in the upper part of the figure. The result is presented as 
median and 25% and 75% percentile. The statistical comparison 
between groups was performed using Mann-Whitney test, with 
a confidence level of 95%. Figure reprinted with permission from 
Banthan Science Publishers Ltd.
with TLR 9 agonists (class A CpG ODN 2216). In 
addition, the expression of intracellular IFN-γ was 
evaluated by flow cytometry after the stimulation of 
PBMC with PMA plus ionomycin.
The most striking finding in this study was the 
demonstration that NK and NKT cells from ESN 
individuals produced a significantly higher amount 
of IFN-γ  in response to stimulation, compared to 
the control group (figure 4). Considering the strong 
antiviral activity of IFN-γ, this finding suggests that 
the production of this cytokine by innate immune 
cells could be associated with the phenomenon of 
natural resistance to HIV-1 exhibited by this group 
of ESN individuals.
A similar frequency of all the evaluated innate immune 
cell subpopulations was found between ESN and 
the control group, while a higher frequency of DC, 
NK and iNKT cells was found in ESN compared to 
SP individuals. The CpG ODN stimulation induced 
similar expression of CD86 and CD69 on innate 
immune cells in all the groups under investigation. 
The secretion of IL-6, IL-10 and TNF-α cytokines 
was similar between ESN and controls, while the 
production of IFN-α  was significantly decreased in 
the SP group. Although, we did not find differences 
between these parameters in this cohort of ESN, 
this does not rule out their relevance in human 
natural resistance to HIV-1.
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Figure 4. Intracellular expression of IFN-γ by NK cells, 
CD3+CD56+ cells and total T cells. Peripheral blood 
mononuclear cells were incubated 4 hrs with PMA/Ionomycin, 
in the presence of Brefeldin A. The expression of IFN-γ was 
determined by intracellular flow cytometry. Horizontal bar in 
graphics corresponds to median values. Statistically significant 
differences between groups are defined in the upper part of the 
figure. The result is presented as median and 25% and 75% 
percentile. The statistical comparison between groups was 
performed using Mann-Whitney test, with a confidence level of 
95%. Figure reprinted with permission from Banthan Science 
Publishers Ltd.
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Adaptive immunity
B cells, CD4+ and CD8+ T lymphocytes participate 
in the control of viral replication in HIV-1-infected 
individuals; in fact, certain reports indicate that 
these cell subpopulations might play an important 
role in preventing the establishment of HIV-1 
infection (67).
Humoral immunity: since the majority of HIV-1 
infections worldwide have been acquired through 
sexual intercourse, the virus enters more frequently 
through the genital mucosa. Therefore, mucosal 
immunity, particularly mediated by secretory IgA 
should play a role in preventing HIV-1 infection. In 
a cohort of sexually ESN individuals high levels of 
anti-HIV-1 IgA were detected in urine and vaginal 
washes, suggesting an association between 
humoral immunity and human natural resistance 
to HIV-1 (68). So far, this parameter has not been 
evaluated in our population of ESN.
Cellular immunity: a high production of Th1 cytokines 
in ESN individuals has been reported (67). In HIV-1 
negative babies born to HIV-1 positive mothers, 
a significantly higher activity of anti-HIV-1 CD8+T 
lymphocytes was found, compared to babies who 
acquired HIV-1 infection (69,70). The presence 
of anti-HIV-1 specific CD8+ T cells has been also 
reported in sexually ESN and health care workers 
who have been accidentally exposed but remain 
seronegative to HIV-1 (71-73). In addition, HIV-1-
gag specific T cells and an increased number of 
HIV-1 specific memory CD4+ and CD8+ T cells 
(CD45RA-/CCR7+) has been reported in ESN (74).
Immune soluble factors
Several soluble factors are postulated as essential 
for the anti-HIV-1 immune response. Their 
antiviral activity is executed through non-cytolytic 
mechanisms, underlining their therapeutic potential 
as a complement of the current antiretroviral 
therapy. These factors include β-chemokines 
(75), CAF (76), SDF-1 (23), IFN-α (77), LIF (78), 
lysozymes, RNases, ASF (79) and α y β defensins 
produced by epithelial and immune cells (80,81).
Defensins are microbicidal peptides of 30 to 48 
cationic amino acids that are produced constitutively 
in response to different microorganisms or in 
response to proinflammatory cytokines (82), 
constituting one of the main mediators of innate 
responses in mucous membranes (8,40). 
α-defensins are found in neutrophils, paneth 
cells and epithelial cells in the urogenital female 
tract (83), (84). Recent investigations reported an 
increased production of α-defensins in CD8+ T 
lymphocytes and cervicovaginal mononuclear cells 
of ESN individuals compared to healthy controls, 
suggesting their role in human natural resistance 
to HIV-1 (85).
To date, 28 human β defensins (hBD) have been 
described. hBD 1 to 4 are the best characterized; 
hBD-1 is constitutively expressed while hBD-2 
whose secretion is induced is present in the skin, 
saliva, plasma and, in higher amounts, in the 
urogenital tract. In addition, its mRNA has been 
located in lungs, the trachea, gut, uterus, liver 
and kidney. hBD-3 is induced in the heart, skeletal 
muscle, placenta, skin, esophagus, gingival 
keratinocytes, trachea and fetal thymus. hBD-4 
is induced in testicles, the uterus, thyroid glands, 
lungs and kidneys (86,87). HIV-1 infection induces 
the expression of the mRNAs for hBD-2 and 3 in 
human oral epithelial cells, inhibiting replication of 
the virus; this inhibition involves direct binding to 
the viral particle and a negative regulation of the 
CXCR4 molecule, suggesting the hBD could play 
an important role in the protection of oral and other 
mucosal surfaces during exposure to HIV-1 (80). 
However, the expression of hBD in oral and genital 
mucosa of ESN individuals has not been explored.
On the other hand, it is postulated that some SNPs 
in the DEFB1 gene, which codes for hBD-1, could 
modulate the function of hBD during exposure to the 
pathogen and to explain their association with some 
biological events including resistance/susceptibility 
to infections. The SNP A692G could be associated 
with the transcription factor NF-κB and expression 
of molecules involved in host defense. The SNP 
A1836G is a probable polyadenylation site, and 
this polymorphism could alter transcription and/
or translation of the gene. The SNP G1654A is 
adjacent to the first of six cysteine residues and 
due to its location it could be involved in the peptide 
function (88,89).
For this reason, we evaluated the association 
between the expression of hBD and the ESN 
condition in individuals who were sexually exposed 
to HIV-1 (90). Peripheral blood, oral, vaginal and 
endocervical mucosal samples were collected from 
47 ESN, 44 SP and 39 healthy controls. In all ESNs 
the presence of the homozygous ∆32 mutation was 
ruled out. The number of mRNA copies for hBD-1, 
-2 and -3 was determined by real time RT-PCR. 
In addition, the polymorphisms A692G/G1654A/
A1836G in the DEFB1 gene were determined by 
restriction fragment length polymorphisms and 
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confirmed by sequencing. The ESN expressed 
significant higher numbers of copies of hBD-2 and 
-3 in the oral mucosa compared to healthy controls 
(figure 5A, 5B). The number of mRNA copies 
for hBD-1 and -2 in vaginal and endocervical 
mucosa was also higher in ESN compared to 
healthy controls, although the differences were not 
statistically significant. These results suggest that 
a higher expression of mRNA for hBD-2 and -3 
could contribute to the natural resistance exhibited 
by this group of ESNs, and once again support 
the hypothesis that defensins, together with other 
soluble factors in this compartment, could be linked 
to a lower risk of HIV transmission via oral sexual 
practices.
Concluding remarks
Despite intensive research on HIV-1 infection, 
there is neither vaccine to prevent this disease 
nor treatment that allows complete eradication of 
this viral infection. Therefore, the identification of 
protective mechanisms to either infection or disease 
progression are required to develop new preventive 
or therapeutic protocols effective in controlling the 
pandemic caused by this virus.
In a setting in which there is sustained exposure 
to infectious virus, the key elements to resist 
HIV-1 infection, and ultimately slow-down disease 
progression, reside mainly on genetic and immune 
components of the host. Several gene products 
participate in recognizing the virus and responding 
to it. Both, the innate and the adaptive immune 
systems participate in a coordinate manner 
through soluble and cellular components in 
order to control viral replication. Considering that 
there are at least three different routes for HIV-1 
transmission, different mechanisms are most likely 
associated with protection in each one of them, or 
at least the magnitude of their participation would 
be variable. Several studies carried out in different 
cohorts of ESNs have not led to the establishment 
of a unique mechanism responsible for protection 
from HIV-1 infection. On the contrary, these studies 
indicate that there is a great heterogeneity in the 
mechanisms so far associated with resistance, 
suggesting a multifactorial process that depends 
on the immunogenetic background of the host. 
However, it is important to point out that the criteria 
used to classify ESN individuals have varied 
between studies, and this might have influenced 
some of the results reported.
With the data so far at hand, it is clear that a 
preventive immunization protocol for HIV-1 
should induce an immediate immune response 
that involves both humoral and cellular adaptive 
immune responses. Innate immunity and antiviral 
mechanisms active in mucosas, in particular soluble 
factors, are the ideal complement for an anti-HIV-1 
response that might allow efficient viral control.
The central question raised is: could these factors, 
at least in combination, be enough to protect against 
HIV-1 infection? Unfortunately, this question is 
still unanswered and its response could only be 
established through collaborative studies including 
various cohorts of ESN individuals throughout the 
world; this would make it possible to determine 
mechanisms of human natural resistance beyond 
Figure 5. Number of mRNA copies for hBD. The number of mRNA copies for hBD with respect to 1000 copies of mRNA for CK19, 
was determined in healthy controls, ESN and HIV-1 infected individuals.
A. Number of mRNA copies for hBD-2 in oral mucosa. 
B. Number of mRNA copies for hBD-3 in oral mucosa. 
Horizontal bar in graphics corresponds to median values. Statistically significant differences between groups are defined in the 
upper part of the figure. The result is presented as median and 75th - 25th percentile. The statistical comparison among groups 
was performed using ANVOA not parametric, Kruskal-Wallis with a confidence level of 95%. Figure reprinted with permission from 
Banthan Science Publishers Ltd.
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the influence of gene variants prevalent in particular 
racial backgrounds.
The magnitude of the current HIV-1 pandemic 
and the permanent difficulties encountered in 
developing therapeutic and preventive measures, 
underlines the fact that we are facing a pathogen 
that only through a natural evolutionary process, 
would humankind be able to face the challenges 
imposed by this infectious agent.
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